Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

Matthew R Smith*, Howard I Scher, Shahneen Sandhu, Eleni Efstathiou, Primo N Lara, Evan Y Yu, Daniel J George, Kim N Chi, Fred Saad, Olof Ståhl, David Olmos, Daniel C Danila, Gary E Mason, Byron M Espina, Xin Zhao, Karen A Urtishak, Peter Francis, Angela Lopez-Gitlitz, Karim Fizazi, GALAHAD investigatorsKlaus Brasso (Member of study group)

*Corresponding author for this work

Fingerprint

Dive into the research topics of 'Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences